On April 14, 2025, Neurogene Inc. amended an agreement with Baker Bros. Advisors to raise the threshold for director nominations from 12.5% to 14.9% of voting stock, and also entered into an exchange agreement for 667,500 shares of common stock for prefunded warrants to purchase 667,563 shares at $0.001 each, resulting in 14,262,066 shares of common stock outstanding post-exchange.